

Supplementary Appendix

The DisCoVeRy Study Group:

The French DisCoVeRy Trial Management Team:

F Ader, Y Yazdanpanah, F Mentre, N Peiffer-Smadja, FX Lescure, J Poissy, L Bouadma, JF Timsit, B Lina, F Morfin-Sherpa, M Bouscambert, A Gaymard, G Peytavin, L Abel, J Guedj, C Andrejak, C Burdet, C Laouenan, D Belhadi, A Dupont, T Alfaiate, B Basli, A Chair, S Laribi, J Level, M Schneider, MC Tellier, A Dechanet, D Costagliola, B Terrier, M Ohana, S Couffin-Cadiergues, H Esperou, C Delmas, J Saillard, C Fougerou, L Moinot, L Wittkop, C Cagnot, S Le Mestre, D Lebrasseur-Longuet, V Petrov-Sanchez, A Diallo, N Mercier, V Icard, B Leveau, S Tubiana, B Hamze, A Gelley, M Noret, E D'Ortenzio, O Puechal, C Semaille.

The DisCoVeRy Steering Committee (members who are not listed in other groups):

T Welte, JA Paiva, M Halanova, MP Kieny

ANRS (France Recherche Nord&Sud SIDA-HIV Hépatites), Paris, France: E Balssa, C Birkle, S Gibowski, E Landry, A Le Goff, L Moachon, C Moins, L Wadouachi, C Paul

Centre Hospitalier Annecy Genevois, France: D Bougon

Centre Hospitalier de Cayenne Andrée Rosemon, Cayenne, France: F Djossou, L Epelboin

Centre Hospitalier Universitaire de Nice, France: J Dellamonica, CH Marquette

Centre Hospitalier Régional de Metz-Thionville, France: C Robert

Centre Hospitalier Régional Universitaire de Nancy, France: S Gibot

Centre Hospitalier de Tourcoing, France: E Senneville, V Jean-Michel

Centre Hospitalier Universitaire de Amiens, France: Y Zerbib

Centre Hospitalier Universitaire de Besançon, France: C Chirouze

Centre Hospitalier Universitaire de Bordeaux, France: A Boyer, C Cazanave, D Gruzon, D Malvy

Centre Hospitalier Universitaire de Dijon, France: P Andreu, JP Quenot

Centre Hospitalier Universitaire de Grenoble Alpes, France: N Terzi

Centre Hospitalier Universitaire de Lille, France: K Faure

Centre Hospitalier Universitaire de Martinique, Fort-de-France, France: C Chabartier

Centre Hospitalier Universitaire de Montpellier, France: V Le Moing, K Klouche

Centre Hospitalier Universitaire de Lyon, France: T Ferry, F, Valour

Centre Hospitalier Universitaire de Nantes, France: B Gaborit, E Canet, P Le Turnier, D Boutoille

Supplementary appendix for :

Ader, F. et al. An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- β -1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results

Centre Hospitalier Universitaire de Reims, France: F Bani-Sadr

Centre Hospitalier Universitaire de Rennes, France: F Benezit, M Revest, C Cameli, A Caro, MJ Ngo Um Tegue, Y Le Tulzo, B Laviolle, F Laine

Centre Hospitalier Universitaire de Saint-Étienne, France: G Thiery

Centre Hospitalier Universitaire de Strasbourg, France: F Meziani, Y Hansmann, W Oulehri, C Tacquard

Centre Hospitalier Universitaire de Toulouse, France: F Vardon-Bounes, B Riu-Poulenc, M Murriss-Espin

Centre Hospitalier Universitaire de Tours, France: L Bernard, D Garot

Groupe Hospitalier de Mulhouse Sud Alsace, France: O Hinschberger

Hospices Civils de Colmar, France: M Martinot

Groupe Hospitalier de Paris Saint Joseph, Paris, France: C Bruel, B Pilmis

Hôpital Avicenne, Assistance Publique – Hôpitaux de Paris, France: O Bouchaud

Centre Hospitalier Universitaire de Nîmes, France: P Loubet, C Roger

Hôpital Bicêtre, Assistance Publique – Hôpitaux de Paris, France: X Monnet, S Figueiredo

Hôpital Bichat - Claude Bernard, Assistance Publique – Hôpitaux de Paris, France: V Godard

Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, France: JP Mira, M Lachatre, S Kerneis

Hôpital Delafontaine, Saint-Denis, France: J Aboab, N Sayre, F Crockett

Hôpital Européen Georges-Pompidou, Assistance Publique – Hôpitaux de Paris, France: D Lebeaux, A Buffet, JL Diehl, A Fayol, JS Hulot, M Livrozet

Hôpital Henri-Mondor, Assistance Publique – Hôpitaux de Paris, France: A Mekontso-Dessap

Hôpital d'Instruction des Armées Bégin, Saint Mandé, France: C Ficko

Hôpital Marie Lannelongue, Le Plessis Robinson, France: F Stefan, J Le Pavec

Hôpital de la Pitié-Salpêtrière, Assistance Publique – Hôpitaux de Paris, France: J Mayaux

Hôpital Saint-Antoine, Assistance Publique – Hôpitaux de Paris, France: H Ait-Oufella

Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris, France: JM Molina

Hôpital Tenon, Assistance Publique – Hôpitaux de Paris, France: G Pialoux, M Fartoukh

Hospices Civils de Lyon, France: J Textoris

Inserm U1018, Université Paris Saclay, CESP, Paris, France: M Brossard, A Essat

Inserm US19-Sc10, Université Paris Saclay, Villejuif, France: E Netzer, Y Riault, M Ghislain

Supplementary appendix for :

Ader, F. et al. An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- β -1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results

Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Épidémiologie et de Santé

Publique (IPLESP), Paris, France: L Beniguel, M Genin

Cliniques Universitaires de Saint Luc, Bruxelles, Belgique: L Belkhir

Centre Hospitalier Régional de la Citadelle, Liège, Belgique: A Altdorfer, V Fraipont

Centro Hospital Universitário de Lisboa Norte, Hospital de Santa Maria, Portugal: S

Braz, JM Ferreira Ribeiro

Centro Hospitalar Universitário São João de Porto, Portugal: JA Paiva, R Roncon

Albuquerque

Hôpitaux Robert Schuman, Luxembourg: M Berna

Luxembourg Institute of Health, Strassen, Luxembourg: M Alexandre

Kepler Universitätsklinikum Linz, Linz, Austria: B Lamprecht

Paracelsus Medical University Salzburg, SCRI-CCCIT and AGMT, Austria: A Egle, R

Greil

AGMT Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria: R Greil

Medizinische Universität Innsbruck, Innsbruck, Austria: M Joannidis

Acknowledgements

We gratefully acknowledge the members of the Data Safety Monitoring Board: Stefano VELLA (chair), Guanhua DU, Donata MEDAGLINI, Mike JACOBS, Sylvie VAN DER WERF, Stuart POCOCK, Phaik Yeong CHEAH, Karen BARNES, Patrick YENI, and the independent statistician Tim COLLIER.

We gratefully acknowledge the chief executive officer of Inserm: Dr. Gilles BLOCH.

We acknowledge the RENARCI network: Marion NORET, Pierre TATTEVIN and Albert SOTTO.

We acknowledge the outstanding support of the Clinical Investigation Centers: Pierre-Olivier GIRODET (CIC1401, Inserm, CHU Bordeaux), Dominique DEPLANQUE (CIC1403, Inserm, CHRU Lille), Jean-Luc CRACOWSKI (CIC1406, Inserm, CHU Grenoble), Michel OVIZE (CIC1407, Inserm, Hospices Civil de Lyon), Bernard TARDY (CIC1408, Inserm, CHU Saint-Etienne), Eric RENARD (CIC1411, Inserm, CHU Montpellier), Jean-Noël TROCHU (CIC1413, Inserm, CHU Nantes), Bruno LAVIOLLE (CIC1414, Inserm, CHU Rennes), Wissam EL HAGE (CIC1415, Inserm, CHU Tours), Odile LAUNAY (CIC1417, Inserm, APHP Cochin), Jean-Sébastien HULOT (CIC1418, Inserm, APHP HEGP), Jean-Christophe CORVOL (CIC1422, Inserm, APHP Pitié-Salpêtrière), Mathieu NACHER (CIC1424, Inserm, CH André Rosemon), André CABIE (CIC1424, Inserm, CHU de la Martinique), Xavier Duval (CIC1425, Inserm, APHP Bichat), Philippe LE CORVOISIER Philippe (CIC1430, Inserm, APHP Mondor), Emmanuel HAFFEN (CIC1431, Inserm, CHU Besançon), Marc BARDOU (CIC1432, Inserm, CHU Dijon), Patrick ROSSIGNOL (CIC1433, Inserm, CHU Nancy), Catherine SCHMIDT-MUTTER (CIC1434, Inserm, CHRU Strasbourg), Olivier RASCOL (CIC1436, Inserm, CHU Toulouse).

We acknowledge the pharmacists: Laure LALANDE (Hospices Civils de Lyon), Marine AUSSÉDAT (Hospices Civils de Lyon), Jennifer LE GRAND (APHP Bichat, PARIS), Laura KRAMER (APHP Bichat, PARIS), Sylvie BRICE (CHRU Lille), Sayah MEGUIG (CHRU Lille), Laurent FLET (CHU Nantes), Martine TCHING-SIN (CHU Nantes), Audrey LEHMANN (CHU Grenoble), Sophie Cerana (CHU Grenoble), Mélanie Minovès (CHU Grenoble), Gwenaël MONNIER (CHU Saint Etienne), Guillaume BECKER (CHRU Strasbourg), Anne HUTT-CLAUSS (CHRU Strasbourg), Sylvia WEHRLÉN-PUGLIESE (CHU Nice), Carine GHIONDA (CHU Nice), Marie-Christine RIGAULT (CHU Nice), Christelle BOCZEK (CHU Nice), Justine BELLEGARDE (CHU Nice), Audrey CASTET-NICOLAS (CHU Montpellier), Jean GALLOT-LAVALLEE (CHU Montpellier), Sophie

Supplementary appendix for :

Ader, F. et al. An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- β -1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results

JUAREZ (CHU Montpellier), Valérie CARRE (CHU Montpellier), Fanny CHARBONNIER-
BEAUPEL (APHP Pitié-Salpêtrière), Carole METZ (APHP Pitié-Salpêtrière), MURIEL
CARVALHO VERLINDE (APHP Mondor), ALAKI THIEMELE (APHP Mondor), delphine
LE FEBVRE DE NAILLY (APHP Mondor), Magali FARINES RAFFOUL (CH Annecy
Genevois), Franck GUERIN (CH Annecy Genevois), Bénédicte BONNARD (CH Annecy
Genevois), Corinne PERNOT (CHU Dijon), Amélie CRANSAC (CHU Dijon), Julie JAMBON
(CHU Dijon), Julien MORLET (CHU Dijon), Clotilde Le Tiec (APHP Bicêtre), Aurélie Barrail
Tran (APHP Bicêtre), Renée Flore ROY EMA (APHP Bicêtre), Grégory Rondelot (CHR Metz
Thionville), Julie Bernez (CHR Metz Thionville), Alexia Hermitte (CHR Metz Thionville),
Hélène Perraud (CHR Metz Thionville), Julien Voyat (CHR Metz Thionville), Laurence Ferrier
(CHR Metz Thionville), Julie Alips (CHR Metz Thionville), Sarah Di-Filippo (CHR Metz
Thionville), Florence Beringuer (CHR Metz Thionville), Michel PREVOT (CHRU Nancy),
Sophie MORICE (CHRU Nancy), Brigitte SABATIER (APHP HEGP), Dominique
ROUSSEAU (APHP HEGP), Marie KROEMER (CHRU Besançon), Julie VARDANEGA
(CHRU Besançon), Magalie VIEILLE (CHRU Besançon), Karen GEORGE (GHR Mulhouse
Sud Alsace), Marion TISSOT (GHR Mulhouse Sud Alsace), Laetitia ARNOUX (GHR
Mulhouse Sud Alsace), Marjorie BRIMBOEUF (GHR Mulhouse Sud Alsace), Philippe
BENOIT (CHU Reims), Frédéric EYVRARD (CHU Toulouse), Caroline SORLI (CHU
Toulouse), Corinne GUERIN (APHP Cochin), Jeremie ZERBIT (APHP Cochin),
MERIAM JARDIN SUZCS (HPJS), SOPHIE RENET (HPJS), Alix DE CHEVIGNY (HPJS),
Anne Daguanel-Nguyen (APHP Saint-Antoine), Clementine Mayala Kanda (APHP Saint-
Antoine), Catherine HAMON-BOUER (CHU Rennes), Pascal LE CORRE (CHU Rennes),
Valentine JASPART-LE DU (CHU Rennes), Roza WILSON (CHU Rennes), Sophie
BODDAERT (CHU Amiens), Florian SMAGGHE (CHU Amiens), Mickael DELAUNAY
(CHU Amiens), Véronique Dubar (CH Tourcoing), Adeline Danielou (CH Tourcoing),
Ghezzoul BELLABES (CHU Bordeaux), Salima ALLAF (APHP Tenon), Jean-Baptiste PAIN
(APHP Tenon), Nina DURET-AUPY (CHU Tours), Hélène BOURGOIN (CHU Tours),
Thierno DIEYE (Hopital Delafontaine), Anais RAZUREL (Hopital Delafontaine), Jean-Louis
LAMAIGNERE (CHU Martinique), Aurélie RISAL (CHU Martinique), Amandine
SGARIOTO (Hôpital des Armées Begin), Claire DAVOINE (APHP Hôpital Saint-Louis),
Vanessa RATHOUIN (Hôpital Avicenne), Blaise NICAISE (CH Andrée Rosemon), Gregory
Gaudillot (CHL, Luxembourg), Emmanuelle Andlauer-Vialette (CHL, Luxembourg), Anne
OTTO (HRS, Luxembourg), Françoise FRANTZEN (HRS, Luxembourg), Nathalie BART
(HRS, Luxembourg), Martin Wolkersdorfer (Landeskrankenhaus, Salzburg), Astrid Vandorpe

Supplementary appendix for :

Ader, F. et al. An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN- β -1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results

(Hôpital Erasme, Bruxelles), Axelle Scarnière (Hôpital Erasme, Bruxelles), Kristel Marquez (Hôpital Erasme, Bruxelles), Nathalie Mathonet (Hôpital Erasme, Bruxelles), Robert Rugwiro (Hôpital Erasme, Bruxelles), Jarode Ducrot (Hôpital Erasme, Bruxelles), Florence Vandenberghe (Hôpital Erasme, Bruxelles), Alexa Jonas (CHR Citadelle, Liège), Valentine Lesenfant (CHR Citadelle, Liège), Blaise Delhauteur (CHR Citadelle, Liège), Annick Peters (CHR Citadelle, Liège), Thi Nguyen (CHR Citadelle, Liège), Jean-François Gouders (CHR Citadelle, Liège), Grégory Opeind (CHR Citadelle, Liège), Adeline GAILLET (Cliniques universitaires Saint Luc, Bruxelles), Ana Carrondo (CHU Lisboa Norte, Hospital Santa Maria, Lisboa), Daniela Ramos (CHU Lisboa Norte, Hospital Santa Maria, Lisboa), Vanessa Côdea (CHU Lisboa Norte, Hospital Santa Maria, Lisboa), Raquel Carneiro (CHU Lisboa Norte, Hospital Santa Maria, Lisboa), Ana Lima (CHU Lisboa Norte, Hospital Santa Maria, Lisboa), Tatiana Bento (CHU Lisboa Norte, Hospital Santa Maria, Lisboa).

We thank the pharmacologists: Marie-Claude Gagneu (CHU Lyon), Minh Lê and Gilles Peytavin (CHU Bichat), Benjamin Hennart (CHU Lille), Matthieu Grégoire (CHU Nantes), Françoise Stanke (CHU Grenoble), Xavier Delavenne (CHU Saint-Etienne), Véronique Kimmel (CHU Strasbourg), Noël Zahr (CHU Pitié-Salpêtrière), Patrice Muret (CHU Besançon), Jean-Yves Jouzeau and Nicolas Gambier (CHU Nancy), Rodolphe Garraffo (CHU Nice), Juliette Descoeur (CHU Montpellier), Valérie Furlan (CHU Bicêtre), Peggy Gandia (CHU Toulouse), Jean-Marc Tréluyer (CHU Cochin), Florian Lemaître (CHU Rennes), Anne-Sophie Hurtel-Lemaire, Youssef Bennis and Sandra Bodeau (CHU Amiens), Gilles Paintaud and François Darrouzain (CHU Tours).

We acknowledge the following individuals from the French Data Management Team of Discovery:

Drug supply: Johanna GUILLON, Anne-Marie TABURET.

Inserm-Transfert: Pascale AUGÉ, Mireille CARALP, Nathalie DUGAS, Florence CHUNG, Julia LUMBROSO.

Clinical Research Unit CHU Bichat-Claude Bernard: Camille COUFFIGNAL.

We thank all the staff members involved in data monitoring.

We thank the COVID-19 Partners Platform and Hervé Le Nagard for data hosting.

We thank Theradis PHARMA, Cagnes-sur-Mer, France.

This study was conducted with the support of GILEAD, SANOFI, MERCK and ABBVIE that provided the study drugs.